Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase NA 2Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Osteosarcoma 2Neuroblastoma 2Lymphoma, Mantle-Cell 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neutropenia 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Multiple Myeloma 1Microphthalmia, Isolated, with Coloboma 5 1Melanoma 1Medulloblastoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Doxorubicin 27Cyclophosphamide 26Radiotherapy 16Gemcitabine 16Filgrastim 11pembrolizumab 10pazopanib 10Radiation 9Docetaxel 9Cisplatin 9fludarabine 7Trabectedin 7Ipilimumab 7Ifosfamide 7Granulocyte Colony-Stimulating Factor 7Etoposide 7Carboplatin 7Busulfan 7Bevacizumab 7olaratumab 6Temozolomide 6Peripheral Blood Stem Cell Transplantation 6Nivolumab 6Mesna 6Melphalan 6selinexor 5Leucovorin 5Irinotecan 5Celecoxib 5Bortezomib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma × pegfilgrastim × Clear all
NCT00004853 2019-11-12

Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
34 enrolled
Sarcoma

Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡